Nick Catlin at Charity Action Duchenne provides an overview of the research into a cure and effective medicines for Duchenne/Becker Muscular Dystrophy.
Jaypreet Dhillon, Editorial Manager of Pharma Publications, Interviews Dr. Hermann Schulz, Chief Executive Officer INTERLAB Central Lab Services – Worldwide GmbH, Munich, Germany, on why paediatric trials are coming into focus now.
Rajendra Kumari and Martin Page at PRECOS look at why, in the attempt to reduce drug attrition and improve clinical predictivity, patient-derived xenograft tumours are being used to improve and refine preclinical modelling.
Robert Kleiman at ERT discusses how centralised ECG trials have emerged as a viable method for helping drug companies provide reliable cardiovascular data in their attempts to achieve regulatory compliance, while also benefiting from significantly improved data accuracy and reliability, time and cost savings, and access to breakthrough technologies.
Juan Gispert at Quintiles provides the first paper in a two part series, describing the pathological role of immunoglobulin E (IgE) in allergic reactions.
Colin Hayward at Premier Research highlights differences and similarities in the paediatric regulatory compliance strategies and priorities of companies in both EU countries and the US.